肿瘤基质金属蛋白酶9的形态学评估可预测肺腺癌手术切除后的生存率。

Morphometric evaluation of tumor matrix metalloproteinase 9 predicts survival after surgical resection of adenocarcinoma of the lung.

作者信息

Pinto Clovis Antônio, Carvalho Paulo Eduardo de Oliveira, Antonângelo Leila, Garippo Ana, Da Silva Alecsander Guillaumon Pereira, Soares Fernando, Younes Riad, Beyruti Ricardo, Takagaki Teresa, Saldiva Paulo, Vollmer Robin T, Capelozzi Vera Luiza

机构信息

Department of Pathology, School of Medicine, University of São Paulo, São Paulo, Brazil.

出版信息

Clin Cancer Res. 2003 Aug 1;9(8):3098-104.

DOI:
Abstract

PURPOSE

Recently, several matrix metalloproteinases (MMPs) have shown promise as prognosticators in non-small cell lung cancer. In this study, we sought to validate the importance of MMP-9 and to study the relationships between MMP-9 and several other tumor or stromal markers.

EXPERIMENTAL DESIGN

We examined MMP-9 and several other markers in tumor tissues from 152 patients with surgically excised adenocarcinomas of the lung. Their preoperative clinical stages were T(1-4)N(0)M(0); however, pathological exam of their resected tissues demonstrated that 33 were stage II, and 64 were stage III. We used immunohistochemistry and morphometry to evaluate the amount of tumor staining for MMP-9, and the outcome for our study was survival time until death from recurrent lung cancer.

RESULTS

Multivariate Cox model analysis demonstrated that pathological stage was significantly related to survival time (P < 0.01), but quantitative staining of the tumor for MMP-9 added prognostic information (P < 3.0 x10(-16)) and was more strongly prognostic than pathological stage. In the subset of pathological stage I patients, staining for MMP-9 was also significantly associated with survival (P < 1.0 x10(-6)), and a cutpoint at the median staining of 11.2% for MMP-9 divided them into two groups with distinctive survival times. Those with MMP-9 > 11.2% had a median survival time of just 11 months. Those with MMP-9 < 11.2% had not reached a median survival and had a mean survival time of >62 months.

CONCLUSIONS

Tumor staining for MMP-9 in resected adenocarcinoma of the lung is strongly related to survival. Patients with >11.2% staining in their tumors comprise a subset with a high hazard for dying of lung cancer and may be an appropriate target for prospective studies of adjuvant chemotherapy after surgical resection.

摘要

目的

最近,几种基质金属蛋白酶(MMPs)在非小细胞肺癌中显示出作为预后指标的潜力。在本研究中,我们试图验证MMP-9的重要性,并研究MMP-9与其他几种肿瘤或基质标志物之间的关系。

实验设计

我们检测了152例手术切除的肺腺癌患者肿瘤组织中的MMP-9和其他几种标志物。他们术前的临床分期为T(1 - 4)N(0)M(0);然而,对其切除组织的病理检查显示,33例为II期,64例为III期。我们使用免疫组织化学和形态计量学来评估肿瘤中MMP-9的染色量,本研究的结果是直至死于复发性肺癌的生存时间。

结果

多变量Cox模型分析表明,病理分期与生存时间显著相关(P < 0.01),但肿瘤中MMP-9的定量染色增加了预后信息(P < 3.0×10⁻¹⁶),并且比病理分期更能有力地预测预后。在病理I期患者亚组中,MMP-9染色也与生存显著相关(P < 1.0×10⁻⁶),MMP-9中位染色量为11.2%的切点将他们分为两组,生存时间明显不同。MMP-9 > 11.2%的患者中位生存时间仅为11个月。MMP-9 < 11.2%的患者尚未达到中位生存期,平均生存时间>62个月。

结论

切除的肺腺癌中MMP-9的肿瘤染色与生存密切相关。肿瘤染色>11.2%的患者是死于肺癌风险较高的亚组,可能是手术切除后辅助化疗前瞻性研究的合适对象。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索